Effects on laboratory parameters of increasing doses of candesartan in 23 type 2 diabetic patients with nephropathy
| Parameter | Placebo | Candesartan dose | ||||
|---|---|---|---|---|---|---|
| 8 mg | 16 mg | 32 mg | ||||
| Renin (mU/l)* | 12 (9–16) | 40 (24–65)† | 49 (31–74)† | 50 (27–84)† | ||
| Ang II (pmol/l)* | 8 (6–10) | 18 (11–27)† | 17 (12–24)† | 19 (11–29)† | ||
| Aldosterone (pmol/l)* | 127 (98–181) | 112 (74–165) | 108 (73–162) | 94 (69–130)† | ||
| Serum potassium (mmol/l) | 4.1 ± 0.1 | 4.2 ± 0.1† | 4.2 ± 0.1† | 4.4 ± 0.1† | ||
| Serum cholesterol (mmol/l) | 5.6 ± 0.2 | 5.5 ± 0.2 | 5.3 ± 0.2 | 5.6 ± 0.3 | ||
| HbA1c (%) | 8.4 ± 0.3 | 8.4 ± 0.3 | 8.5 ± 0.2 | 8.4 ± 0.2 | ||
| Hemoglobin (mmol/l) | 8.6 ± 0.2 | 8.3 ± 0.2† | 8.2 ± 0.2† | 8.2 ± 0.2† | ||
| Protein intake (g/kg/24-h) | 1.0 ± 0.06 | 1.0 ± 0.06 | 0.9 ± 0.05 | 0.9 ± 0.05 | ||
| Urinary sodium excretion (mmol/24-h) | 219 ± 20 | 213 ± 12 | 205 ± 19 | 211 ± 17 | ||